Recruiting EARLY_PHASE1 INTERVENTIONAL 2-arm NCT06328686

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

Arginine With Whole Brain Radiation Therapy for the Treatment of Brain Metastases

Sponsor: Emory University

Conditions Metastatic Malignant Neoplasm in the Brain Metastatic Malignant Solid Neoplasm

Interventions Arginine Biospecimen Collection Computed Tomography Magnetic Resonance Imaging Spectroscopy Whole-Brain Radiotherapy

Updated 7 times since 2024 Last updated: Sep 16, 2025 Started: Sep 5, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Metastatic Malignant Neoplasm in the Brain and Metastatic Malignant Solid Neoplasm and is currently actively recruiting participants. Emory University leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Oct 2025 — Present [monthly]

Recruiting EARLY_PHASE1
Oct 2024 — Oct 2025 [monthly]

Recruiting EARLY_PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Jul 2024 — Aug 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1

▶ Show 2 earlier versions

May 2024 — Jul 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Apr 2024 — May 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Emory University
National Cancer Institute (NCI)

Data source: Emory University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Atlanta, United States